Mutated polypeptides, compositions comprising the same, and uses thereof
AssigneeInterius Biotherapeutics, Inc.
InventorsBruce C. Schnepp, Philip R. Johnson
Life of this patent
Estimating the term…
Abstract
Provided for herein are viral particles comprising a heterologous viral glycoprotein and a targeting moiety, wherein the targeting moiety comprises a polypeptide comprising a formula of T-S1, wherein T is a target binding domain and S1 is a stalk portion. The stalk portion may comprise a variant Fe domain. The stalk portion may comprise a flexible polypeptide domain. The targeting moiety comprising the formula T-S1 may be incorporated into a viral particle to assist with targeting such particles to a specific cell type. Also provided for herein are compositions comprising the same, and methods of using the same.
Claims33
A viral particle comprising a heterologous viral glycoprotein and a targeting moiety, wherein the targeting moiety comprises a polypeptide having the formula T-S1, wherein T is a target binding domain and Sis a stalk portion,
- wherein the heterologous viral glycoprotein is a VSV-G polypeptide comprising an amino acid sequence having at least 95% identity to SEQ ID NO:
- 2;
- wherein the target binding domain (T) comprises a scFv antibody that binds to CD7, wherein the scFv comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence of SEQ ID NO:
- 30, a HCDR2 comprising the amino acid sequence of SEQ ID NO:
- 31, and a HCDR3 comprising the amino acid sequence of SEQ ID NO:
- 32;
- and wherein the light chain variable region comprises a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence of SEQ ID NO:
- 33, a LCDR2 comprising the amino acid sequence of SEQ ID NO:
- 34, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:
- 35;
- and
- wherein the stalk portion S1 comprises a Fc protein comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:
- 103, and wherein the S1 stalk portion is attached to the surface of the viral particle through a transmembrane domain.
The viral particle 1, wherein the VSV-G polypeptide comprises a mutation at position 182 as compared to SEQ ID NO:
- 2.
The viral particle 1, wherein the VSV-G polypeptide comprises a I182E or I182D mutation as compared to SEQ ID NO:
- 2.
Dependencies are inferred from the claim text.